Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EPRX Eupraxia Pharmaceuticals

Trading 04-02 12:57:32 EDT

7.05

-0.28

-3.89%

High7.41	Low7.00	Vol74.54K
Open7.13	D1 Closing7.33	Amplitude5.59%
Mkt Cap433.29M	Tradable Cap321.87M	Total Shares61.50M
T/O532.06K	T/O Rate0.16%	Tradable Shares45.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EPRX","market":"US","secType":"STK","nameCN":"Eupraxia Pharmaceuticals","latestPrice":7.045,"timestamp":1775148944909,"preClose":7.33,"halted":0,"volume":74539,"delay":0,"changeRate":-0.03888130968622103,"floatShares":45687900,"shares":61503200,"eps":-1.0088483,"marketStatus":"Trading","change":-0.285,"latestTime":"04-02 12:57:32 EDT","open":7.13,"high":7.41,"low":7,"amount":532057.89122,"amplitude":0.055935,"askPrice":7.07,"askSize":854,"bidPrice":7.02,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.0088483,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1775160000000},"marketStatusCode":2,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":7.33,"preHourTrading":{"tag":"盘前","latestPrice":7.75,"preClose":7.33,"latestTime":"09:16 EDT","volume":439,"amount":3218.2899035,"timestamp":1775135814083,"change":0.42,"changeRate":0.057299,"amplitude":0.057299},"postHourTrading":{"tag":"盘后","latestPrice":7.33,"preClose":7.33,"latestTime":"17:34 EDT","volume":3124,"amount":22899.18,"timestamp":1775079267032,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.43011},"requestUrl":"/m/hq/s/EPRX","defaultTab":"news","newsList":[{"id":"2624513009","title":"Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2624513009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624513009?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:16","pubTimestamp":1775045814,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Eupraxia Pharmaceuticals yesterday and set a price target of $19.00. The compan...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/eupraxia-pharmaceuticals-eprx-receives-a-buy-from-cantor-fitzgerald-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/eupraxia-pharmaceuticals-eprx-receives-a-buy-from-cantor-fitzgerald-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621085647","title":"Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2621085647","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621085647?lang=en_us&edition=fundamental","pubTime":"2026-03-24 01:59","pubTimestamp":1774288740,"startTime":"0","endTime":"0","summary":"William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/23/X-ray-Anterior-Or-Front-View-Of-The-Esop.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/23/X-ray-Anterior-Or-Front-View-Of-The-Esop.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/03/51415703/eupraxia-pharmaceuticals-boasts-900-million-peak-sales-potential-analyst","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/03/51415703/eupraxia-pharmaceuticals-boasts-900-million-peak-sales-potential-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SKIS","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621706451","title":"Eupraxia Pharmaceuticals Initiated at Outperform by William Blair","url":"https://stock-news.laohu8.com/highlight/detail?id=2621706451","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621706451?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:04","pubTimestamp":1774271040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 23, 2026 09:04 ET (13:04 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621772870","title":"Eupraxia: Differentiated Once-Yearly EoE Therapy and Platform Expansion Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2621772870","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621772870?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:15","pubTimestamp":1774260948,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (EPRX) has received a new Buy rating, initiated by William Blair analyst, Lachlan Hanbury Brown. Lachlan Hanbury Brown has...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/eupraxia-differentiated-once-yearly-eoe-therapy-and-platform-expansion-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/eupraxia-differentiated-once-yearly-eoe-therapy-and-platform-expansion-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621793885","title":"Eupraxia Pharmaceuticals (EPRX) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2621793885","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621793885?lang=en_us&edition=fundamental","pubTime":"2026-03-21 22:56","pubTimestamp":1774105005,"startTime":"0","endTime":"0","summary":"In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of $16.00. Sl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/eupraxia-pharmaceuticals-eprx-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/eupraxia-pharmaceuticals-eprx-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620747216","title":"HD Renewable Energy Secures JPY 5.4 Billion Financing for Hokkaido BESS in Japan's First Grid-Scale Battery Green Bond","url":"https://stock-news.laohu8.com/highlight/detail?id=2620747216","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620747216?lang=en_us&edition=fundamental","pubTime":"2026-03-19 14:00","pubTimestamp":1773900000,"startTime":"0","endTime":"0","summary":"TAIPEI, March 19, 2026 /PRNewswire/ -- HD Renewable Energy , a leading international smart energy company, announced that its Helios 50MW grid-scale battery energy storage system  project in Hokkaido, Japan, has secured project financing of approximately JPY 5.4 billion.HDRE secures project financing for the Hokkaido Helios project, marking Japan’s first Green Project Bond for grid-scale BESS.The financing was arranged with the support of Nomura Capital Investment and Nomura Securities, and raised through a green project bond, marking Japan's first green project bond backed by grid-scale battery storage assets. The transaction highlights growing interest from global capital markets in energy storage infrastructure and market-driven power trading models.The financing adopts a project finance trust beneficiary right structure , with the HDRE Group serving as the asset manager. The Helios project operates under a merchant model, generating revenue primarily through electricity trading in ","market":"other","thumbnail":"https://mma.prnewswire.com/media/2937687/1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2937687/1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/hd-renewable-energy-secures-jpy-5-4-billion-financing-for-hokkaido-bess-in-japans-first-grid-scale-battery-green-bond-302718269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823411888.USD","LU0942090050.USD","LU2361044865.SGD","EPRX","SPO.AU","US12M.BOND","LU1674673691.USD","BESS","JPY","LU1035775433.USD","US2Y.BOND","US6M.BOND","LU2361044949.HKD","TLTW","LU0238689110.USD","BK4139","BK4504","US30Y.BOND","IE00BKVL7J92.USD","LU1496350171.SGD","HD","LU0823434740.USD","US3Y.BOND","US7Y.BOND","BK4585","LU1551013425.SGD","LU0689472784.USD","LU0943347566.SGD","IE00B1XK9C88.USD","BK4566","IE00BWXC8680.SGD","LU1929549753.HKD","IE00BSNM7G36.USD","LU2756315318.SGD","LU1093756168.USD","TMF","BK4581","US5Y.BOND","LU1914381329.SGD","BK4533","LU2756315664.SGD","5AL.SI","US10Y.BOND","LU2361045086.USD","BK4534","LU0823434583.USD","LU1989772840.SGD","LU0354030438.USD","LU1162221912.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620610269","title":"Eupraxia Pharmaceuticals: Durable EP-104GI Data and Upcoming Catalysts Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620610269","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620610269?lang=en_us&edition=fundamental","pubTime":"2026-03-19 02:35","pubTimestamp":1773858939,"startTime":"0","endTime":"0","summary":"Bloom Burton analyst David Martin PhD maintained a Buy rating on Eupraxia Pharmaceuticals today and set a price target of $14.00. David Martin PhD ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-durable-ep-104gi-data-and-upcoming-catalysts-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/eupraxia-pharmaceuticals-durable-ep-104gi-data-and-upcoming-catalysts-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EP","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620420382","title":"Sector Update: Health Care Stocks Mixed Premarket Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420382","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420382?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:16","pubTimestamp":1773753404,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF  down 0.1% and the iShares Biotechnology ETF  0.4% higher.Eupraxia Pharmaceuticals  shares were up more than 1% after the company said data from its ongoing trial evaluating EP-104GI for eosinophilic esophagitis treatment showed 59% of patients achieved clinical remission at 12 weeks.Monte Rosa Therapeutics  stock was down 1% after the company reported that it swung to a Q4 net loss as collaboration revenue declined during the period.Lensar  shares were down more than 24% after the company said it has reached an agreement with Alcon  to terminate their planned merger.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALC","XLV","GLUE","BK4534","LABU","BK4581","BK4082","BK4139","BK4585","LU1804176565.USD","BK4198","IBB","EPRX","BK4539","BK4588","ALC.AU","XBI","LNSR","LU2265009873.SGD","BK7094"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620442442","title":"Eupraxia Pharmaceuticals Says Eosinophilic Esophagitis Treatment Trial Shows Over Half of Patients in Remission","url":"https://stock-news.laohu8.com/highlight/detail?id=2620442442","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620442442?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:21","pubTimestamp":1773750068,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals  said Tuesday data from its ongoing trial evaluating EP-104GI for eosinophilic esophagitis treatment showed 59% of patients achieved clinical remission at 12 weeks.At 24 weeks, 76% of the patients maintained clinical remission, Eupraxia said.No serious adverse events have been reported, and the drug continues to be well tolerated at all dose levels by patients, the company said.Eupraxia said that top-line data from the phase 2b portion of the trial is expected in Q3.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620721429","title":"Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2620721429","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620721429?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:28","pubTimestamp":1773746926,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ). On March 17, 2026, Eupraxia Pharmaceuticals reported new six‑month sy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-posts-strong-six-month-eoe-data-for-ep-104gi-as-resolve-trial-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-posts-strong-six-month-eoe-data-for-ep-104gi-as-resolve-trial-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EP","EPRX","BK4139","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620584429","title":"Eupraxia Pharmaceuticals’ esophagitis candidate shows symptom decrease","url":"https://stock-news.laohu8.com/highlight/detail?id=2620584429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620584429?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:12","pubTimestamp":1773745922,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (EPRX) announced positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-esophagitis-candidate-shows-symptom-decrease-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-esophagitis-candidate-shows-symptom-decrease-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426421","title":"Eupraxia Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426421","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426421?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:06","pubTimestamp":1773745560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2026 07:06 ET (11:06 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426290","title":"Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426290","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426290?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:00","pubTimestamp":1773745200,"startTime":"0","endTime":"0","summary":"For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257002/0/en/Eupraxia-Pharmaceuticals-Reports-Six-Month-Symptom-Data-from-the-Highest-Dose-Cohort-in-its-Ongoing-Phase-1b-2a-RESOLVE-Trial-in-Eosinophilic-Esophagitis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620985443","title":"HD Renewable Energy Showcases 3GW Japan Pipeline and Power Trading Strategy at Tokyo Smart Energy Week 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620985443","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620985443?lang=en_us&edition=fundamental","pubTime":"2026-03-17 14:00","pubTimestamp":1773727200,"startTime":"0","endTime":"0","summary":"TAIPEI, March 17, 2026 /PRNewswire/ -- HD Renewable Energy Co., Ltd., a leading smart energy company from Taiwan, is participating in the 25th Smart Energy Week in Tokyo starting today. At the exhibition, the company showcases three core solutions—energy storage integration, power trading, and EV charging—while highlighting its latest project developments and growing presence in Japan.In the capacity market, HDRE actively participates in Japan's Long-Term Decarbonization Power Source Auction . In 2024, the company secured 100MW, becoming the first Taiwanese company to win a project under the program. In 2025, it secured another 300MW and plans to bid for approximately 800MW in the upcoming round, targeting long-term revenue supported by the Japanese government's 20-year subsidy scheme.In power trading, the group's subsidiary Star Trade combines AI-driven price forecasting with HDRE's energy storage assets and dispatch capabilities to develop the Power Bank model. The platform provides ","market":"other","thumbnail":"https://mma.prnewswire.com/media/2935618/image.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2935618/image.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/hd-renewable-energy-showcases-3gw-japan-pipeline-and-power-trading-strategy-at-tokyo-smart-energy-week-2026-302715534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1551013342.USD","LU2361044865.SGD","LU1236620834.HKD","LU1035775433.USD","IE00BKVL7J92.USD","BK6088","BK4534","LU0823434740.USD","EPRX","LU1093756325.SGD","PW","BK4504","LU0354030438.USD","LU1989772840.SGD","LU0320765646.SGD","BK4550","HD","LU2756315664.SGD","BK4566","LU0234572021.USD","BK4585","LU1674673691.USD","BK4084","LU1674673428.USD","LU2461242641.AUD","LU1496350502.SGD","BK4588","LU0689472784.USD","LU1929549753.HKD","LU1989772923.USD","LU1093756168.USD","BK6522","5AL.SI","LU0079474960.USD","LU1496350171.SGD","BK4581","LU0942090050.USD","IE00BWXC8680.SGD","LU0354030511.USD","LU2361044949.HKD","LU0823411888.USD","LU1162221912.USD","LU0823434583.USD","LU0098860793.USD","IE00BSNM7G36.USD","LU1914381329.SGD","LU2756315318.SGD","LU0943347566.SGD","LU0820561909.HKD","BK4083"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620416626","title":"Eupraxia (EPRX): Robust Cash Runway and Promising EP-104GI GI Pipeline Create Attractive Risk‑Reward and Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620416626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620416626?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:05","pubTimestamp":1773709517,"startTime":"0","endTime":"0","summary":"Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Eupraxia Pharmaceuticals. The associated price target remains the same w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/eupraxia-eprx-robust-cash-runway-and-promising-ep-104gi-gi-pipeline-create-attractive-risk‑reward-and-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/eupraxia-eprx-robust-cash-runway-and-promising-ep-104gi-gi-pipeline-create-attractive-risk‑reward-and-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","EP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619166674","title":"Eupraxia Pharmaceuticals Q4 EPS $(0.37) Misses $(0.16) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2619166674","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619166674?lang=en_us&edition=fundamental","pubTime":"2026-03-13 14:59","pubTimestamp":1773385170,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.16) by 131.25 percent. This is a 68.18 percent decrease over losses of $(0.22) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51233361/eupraxia-pharmaceuticals-q4-eps-0-37-misses-0-16-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619740152","title":"Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619740152","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619740152?lang=en_us&edition=fundamental","pubTime":"2026-03-13 09:03","pubTimestamp":1773363780,"startTime":"0","endTime":"0","summary":"VICTORIA, British Columbia, March  12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/13/3255235/0/en/Eupraxia-Pharmaceuticals-Reports-Fourth-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617637051","title":"Eupraxia Pharmaceuticals Raises US$63.2 Million in February 2026 Equity Offering to Advance GI Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2617637051","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617637051?lang=en_us&edition=fundamental","pubTime":"2026-03-07 03:17","pubTimestamp":1772824638,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has issued an update. On February 20, 2026, Eupraxia Pharmaceuticals closed a public offering of 7,607,145...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-raises-us63-2-million-in-february-2026-equity-offering-to-advance-gi-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-raises-us63-2-million-in-february-2026-equity-offering-to-advance-gi-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4215","BK4139","BK4588","EQR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616356207","title":"Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2616356207","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616356207?lang=en_us&edition=fundamental","pubTime":"2026-03-02 23:16","pubTimestamp":1772464561,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Eupraxia Pharmaceuticals, with a price target of $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/eupraxia-pharmaceuticals-eprx-receives-a-buy-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/eupraxia-pharmaceuticals-eprx-receives-a-buy-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613779798","title":"Eupraxia Pharmaceuticals (EPRX) Gets a Buy from Bloom Burton","url":"https://stock-news.laohu8.com/highlight/detail?id=2613779798","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613779798?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:27","pubTimestamp":1771928876,"startTime":"0","endTime":"0","summary":"In a report released yesterday, David Martin PhD from Bloom Burton initiated coverage with a Buy rating on Eupraxia Pharmaceuticals and a price tar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/eupraxia-pharmaceuticals-eprx-gets-a-buy-from-bloom-burton-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/eupraxia-pharmaceuticals-eprx-gets-a-buy-from-bloom-burton-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eupraxiapharma.com","stockEarnings":[{"period":"1week","weight":0.0353},{"period":"1month","weight":-0.1169},{"period":"3month","weight":-0.0291},{"period":"6month","weight":0.253},{"period":"1year","weight":1.2353},{"period":"ytd","weight":-0.0291}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0454},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0209},{"period":"1year","weight":0.168},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.","exchange":"NASDAQ","name":"Eupraxia Pharmaceuticals","nameEN":"Eupraxia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eupraxia Pharmaceuticals(EPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eupraxia Pharmaceuticals,EPRX,Eupraxia Pharmaceuticals股票,Eupraxia Pharmaceuticals股票老虎,Eupraxia Pharmaceuticals股票老虎国际,Eupraxia Pharmaceuticals行情,Eupraxia Pharmaceuticals股票行情,Eupraxia Pharmaceuticals股价,Eupraxia Pharmaceuticals股市,Eupraxia Pharmaceuticals股票价格,Eupraxia Pharmaceuticals股票交易,Eupraxia Pharmaceuticals股票购买,Eupraxia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eupraxia Pharmaceuticals(EPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}